Skip to content
Screener

ArriVent BioPharma, Inc. AVBP Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

EPS-$0.78Beat by $0.09
EPS estimate-$0.87

Next report

Nov 16, 2026 (in 2 months)
Revenue estimate$800.0K
EPS estimate-$1.07

Financials

Q4 2025

Income statement

See full
Operating income-$38.8M-63.8%
Net income-$35.5M-72.3%
EPS (diluted)-$0.78-27.9%

Balance sheet

See full
Cash & equivalents$45.5M-38.7%
Total debt$14.0K-92.0%
Total equity$307.2M+19.2%
Total assets$333.2M+21.2%

Cash flow

See full
Operating cash flow-$30.7M-89.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$830.58M-7.5%
Enterprise value$785.05M-4.7%

Returns & leverage

See full
Return on equity-58.9%—
Debt / equity0×—
Current ratio12.8×-0.3×

FAQ

When did ArriVent BioPharma, Inc. report Q4 2025 earnings?
ArriVent BioPharma, Inc. (AVBP) reported Q4 2025 earnings on March 5, 2026 before market open.
What were ArriVent BioPharma, Inc.'s Q4 2025 revenue and EPS?
ArriVent BioPharma, Inc. reported eps of $-0.78 for Q4 2025.
Did ArriVent BioPharma, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.87 by $0.09.
How did ArriVent BioPharma, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 30.0% from $-0.60.
Where can I find ArriVent BioPharma, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-024112) and the 10-K periodic report (0001104659-26-024127) directly on SEC EDGAR. The filing index links above go to sec.gov.